SPL 2.11% 9.3¢ starpharma holdings limited

Ann: Quarterly Activities Report & Appendix 4C, page-2

  1. 321 Posts.
    lightbulb Created with Sketch. 84
    I not think this good. Sadly Sales figures are pathetic and the cabazitaxel and docetaxel trials not likely to finish recruiting this CY so not expect there will be study completion until well into 2023 IMO.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.